Tracking Cathie Wood: Added over 240,000 shares of NVIDIA, continued to reduce AMD holdings to adjust allocation

As of market close on Friday, August 28, 2026 (Eastern Time), the three major U.S. stock indices closed lower. The S&P 500 ended at 7,711.76, down 0.25%; the Nasdaq Composite closed at 26,402.42, down 0.52%; and the Dow Jones Industrial Average finished at 53,559.99, edging down 0.02%. The broader market showed signs of consolidation, with capital seeking new directions at high levels, making liquidity management a key focus for institutional investors.

In the face of slight market volatility, Cathie Wood continues to prune weaker positions and strengthen stronger ones around disruptive innovation. Capital is being reallocated to sectors with deeper moats, namely AI computing power and precision medicine, while positions are moderately adjusted to cope with market fluctuations.

Symbols

Buy Direction: Increase exposure to core AI computing infrastructure and the precision medicine sector

Buy $NVIDIA (NVDA.US)$ 243,707 shares. Looking back to January 2023, on the eve of the AI boom, Cathie Wood completely liquidated her NVIDIA position in the flagship ARKK fund, causing her to miss NVIDIA's most explosive main uptrend in recent years and sparking intense market controversy.

Entering June of this year, Cathie Wood began to shift her stance. After aggressively purchasing 300,000 shares in June, she decisively increased her position during the window of opportunity created by NVIDIA's better-than-expected earnings report and the subsequent pullback in its stock price last Friday. As the absolute core of AI embodied intelligence and computing power infrastructure, Cathie Wood likely continues to view NVIDIA as indispensable in the global tech giants' arms race.

Buy $Veracyte (VCYT.US)$ 213,073 shares. Precision medicine is one of ARK's four core investment themes. This increase in holdings may reflect recognition of its moat in genetic diagnostic technology and its long-term growth potential. During the process of capital reallocation, diagnostic stocks with technological moats may become choices that offer both defensive and offensive capabilities.

Buy $Broadcom (AVGO.US)$ 55,131 shares. As a key supplier of networking chips and customized AI computing power, this increase in holdings may aim to capture the benefits of data center and broadband infrastructure upgrades. This move may indicate optimism about its role as an 'invisible champion' in the AI industry chain, thereby improving the layout of the AI ecosystem.

Buy $Intellia Therapeutics (NTLA.US)$ 54,424 shares. Gene editing technology is at a critical stage of commercialization. This increase in holdings may reflect confidence in the long-term disruptive potential of its CRISPR technology platform. By increasing exposure to frontier biotechnology, ARK may be preparing for future valuation reshaping.

Buy 9,755 shares of 3iQ Solana Staking ETF (SOLQ.U.US). Blockchain and crypto assets are one of the disruptive innovations tracked by ARK. Buying a Solana-related ETF may represent optimism about the scalability of its ecosystem. This could also be a liquidity management strategy, flexibly capturing potential opportunities in the crypto market through ETFs.

Buy $Scribe Therapeutics (SCTX.US)$ 191 shares. Although the number of shares added is small, this move may represent continuous tracking and a small-scale position in the field of gene editing tool development. This aligns with ARK's investment logic of casting a wide net in early-stage frontier technologies to find future breakout points.

Sell direction: Adjust holdings in the chip competitive landscape to reduce concentration.

Sell $Advanced Micro Devices (AMD.US)$ 156,286 shares. While increasing positions in NVIDIA, reducing holdings in AMD is clearly a move of capital reallocation and portfolio rebalancing. This may reflect a preference for concentrating investments on the leader with absolute monopoly status in the AI computing chip sector, in order to reduce competitive risk in the portfolio.

Sell $Twist Bioscience (TWST.US)$ 1,425 shares. This slight reduction may be a routine portfolio adjustment to manage concentration in a single holding. It could also be a capital reallocation strategy within the synthetic biology sector during broader market volatility, aimed at shedding weaker positions and retaining stronger ones.

Futubull [Opportunity Page] has launched tracking for celebrity portfolio opportunities! Choose from multiple celebrity holdings, follow big investors' layouts with one click, precisely lock in high-quality targets, and invest with greater confidence!

255K Views